- Title: Diagnostic-avoiding *Chlamydia trachomatis* variants detected in cervical and endometrial
   specimens from women during 16S microbiome profiling.
- 3
- 4 Authors: Sangmi Jeong<sup>1</sup>, Tammy Tollison<sup>1</sup>, Hayden Brochu<sup>1</sup>, Hsuan Chou<sup>1</sup>, Tammy Yu<sup>2</sup>,
- 5 Priyanka Baghaie<sup>2</sup>, Kacy S. Yount<sup>2</sup>, Toni Darville<sup>2</sup>, Harold C Wiesenfeld<sup>3</sup>, Sharon L Hillier<sup>3</sup>, Xinxia
- 6 Peng<sup>1</sup> and Catherine M. O'Connell<sup>2</sup>
- 7 <sup>1</sup>North Carolina State University
- 8 <sup>2</sup>University of North Carolina at Chapel Hill
- 9 <sup>3</sup>University of Pittsburgh School of Medicine and the Magee-Womens Research Institute

10

- 11 **Correspondence:** Catherine O'Connell, PhD, University of North Carolina at Chapel Hill, 8340B
- 12 MBRB, CB# 7509, 111 Mason Farm Road, Chapel Hill, NC 27599-7509, phone (919) 962-3422,

13 fax:(919) 966-7277, <u>catherine.oconnell@unc.edu</u>

- 14 Alternate corresponding author: Xinxia Peng, PhD, North Carolina State University, Raleigh, NC
- 15 27695, phone (919) 515-4481, fax: (919)-513-6464, <u>xpeng5@ncsu.edu</u>

16

17 Keywords: NAAT, chlamydia, gonorrhea, microbiome, 16S rRNA, false negative, 23S

## 18 Abstract:

Background: Performance of a 16S rRNA analysis of the cervicovaginal microbiome of 220 participants recruited into the T Cell Response against Chlamydia (TRAC) cohort between February 2011 and August 2014 in Allegheny County, Pennsylvania USA detected DNA encoding chlamydial 16S rRNA in samples from seven participants whose tests were negative for *Chlamydia trachomatis* (CT) and DNA encoding gonococcal 16S rRNA from five participants whose tests were negative for *Neisseria gonorrhoeae* (NG) infection with the Aptima Combo2 assay (Hologic).

Methods: We used targeted PCR amplification followed by sequencing to characterize the chlamydial 23S rRNA locus and qPCR to detect gonococcal DNA in residual diagnostic swab eluates or DNA used to generate 16S rRNA libraries.

Results: Discrepant specimens that contained chlamydial DNA carried a diagnostic-avoidant, G1526A variant in the 23S rRNA locus identical to variants previously detected in Finland, Denmark, and the UK. PCR validation of gonococcal DNA was confirmed for all participants whose tests were negative, with stochastic effects consistent with infection levels close to the limit of detection by the diagnostic assay.

Conclusions: These data indicate that this probe-avoidant CT mutant, and possibly others, were circulating in the northeastern US prior to their detection and characterization in 2019. Although infrequent, documentation of false negative results for CT indicates a need for clinicians to consider performance of a second test that uses alternate PCR targets if patients have persistent symptoms or have known contact to an infected sex partner and their initial NAAT is negative.

39

# 41 Background:

42 Performing cross sectional or longitudinal research studies investigating natural immunity 43 or immunopathogenesis of sexually transmitted infections (STI) in humans can be a complex, 44 time consuming and expensive undertaking. Efforts to mine all data associated with infection or 45 disease cohorts are often extensive and protracted. Such is the case for the TRAC (T cell 46 Response Against Chlamydia) cohort, a group of 246 cisgender women at elevated risk for 47 chlamydial infection who enrolled between February 2011 and August 2014 while presenting to 48 the Allegheny County, PA Health Department's Sexually Transmitted Diseases Clinic for STI 49 testing and/or management. The TRAC study sought to profile cell mediated responses 50 associated with protection against ascending C. trachomatis (CT) infection (from the cervix to 51 endometrium) or against CT reinfection [1, 2]. Since completion of enrollment, data obtained from 52 participant samples and questionnaire responses have been used to profile antibody [1, 3-5], T 53 cell antigen-specific responses [2], and to determine risk factors for ascending infection. Using 54 modern molecular techniques, we quantified pathogen burden [1, 2], local cytokine secretion [6] 55 and used genetic profiling techniques to search for biomarkers predictive of disease or reinfection 56 risk [7-9]. Secondary investigations have also assessed the impact of Mycoplasma genitalium 57 infection in this population [10]. Fundamental to the success of these analyses has been accurate 58 classification of study participants according to infection status at enrollment and during 59 subsequent follow up, so enrollee infection status was assigned according to the outcome of an 60 FDA-cleared STI diagnostic NAAT test performed at the study visit, the results of which were used 61 to inform clinical care. Infrequently, discrepant results were observed between research PCR 62 assays detecting chlamydial loci and results obtained using the Aptima Combo 2® assay (AC2), 63 manufactured by Hologic, Inc., a commercially available nucleic acid amplification test (NAAT) 64 for CT and Neisseria gonorrhoeae (NG), targeting 23S ribosomal RNA (rRNA) and 16S rRNA in 65 these bacteria, respectively. However, we could not exclude the possibility of cross-contamination

from the environment or chlamydia-infected specimens, particularly with repurposed, reprocessed
 convenience samples, e.g., leftover transport medium.

68 The availability of pristine "future use" vaginal swabs collected from the same cohort and 69 stored since enrollment provided an opportunity to reexamine these discrepant results while 70 determining cervicovaginal microbiome profiles that associated with ascending chlamydial 71 infection [11]. We performed a 16S rRNA gene genomic DNA based microbiome analysis on the 72 entire cohort and detected chlamydial DNA in samples from seven participants whose tests were 73 negative for CT and gonococcal DNA from five participants whose tests were negative for NG 74 with the AC2 assay. PCR amplification and subsequent sequencing using primers directed 75 against the 23S rRNA locus revealed that some of the specimens contained chlamydial DNA 76 carrying a diagnostic-avoidant single nucleotide polymorphism (SNP) that likely contributed to 77 misclassification. These data indicate that this mutant, and possibly others, were circulating in the 78 northeastern US prior to their detection and characterization in the United Kingdom and Denmark 79 in 2019 and subsequently [12-14]. Discrepant NG detection reflected very low gonococcal loads 80 that challenged the limit of resolution for the NAAT. Although infrequent, documentation of false 81 negative results for CT or NG may indicate a need for clinicians to consider performance of a 82 second test that uses alternate or additional PCR probes.

83

# 84 Methods:

T Cell Response against Chlamydia (TRAC) Cohort (246 participants). This cohort was composed of young (median age, 21 years; range, 18-35 years) cis-gender women at high risk for the acquisition of CT [1]. Criteria indicating high-risk status included > 3 sexual partners in the previous 6 months,  $\leq$  14 years of age at sexual debut, history of pelvic inflammatory disease (PID), the presence of mucopurulent cervicitis on exam, or sexual contact with a partner known

90 to be infected with CT or NG or non-gonococcal non-chlamydial urethritis. Women with a current 91 diagnosis of PID were excluded. Additional exclusion criteria were pregnancy, uterine procedure 92 or miscarriage in the preceding 60 days, menopause, hysterectomy, antibiotic therapy in the 93 preceding 14 days, and allergy to study medications. TRAC participants were enrolled into a 94 longitudinal study designed to investigate T cell responses important for protection from incident 95 chlamydial infection over 12 months of follow-up between February 2011 and August 2014 and 96 were recruited from the Allegheny County Health Department's Sexually Transmitted Diseases 97 Clinic, UPMC Magee-Womens Hospital (MWH) Ambulatory Care Clinic, and the Reproductive 98 Infectious Disease Research Unit at MWH in Pittsburgh PA. Participants provided informed 99 consent at the time of enrollment and completed questionnaires regarding obstetric/gynecologic 100 history, behavioral practices, sex exposure, contraceptive methods, and symptoms. Clinical, 101 histological, and microbiological testing was performed, and blood and endometrial samples were 102 obtained after enrollment, after which all participants received single-dose agents for gonorrhea 103 (ceftriaxone, 250 mg intramuscularly) and chlamydia (azithromycin, 1 g orally). Participants in this 104 cohort were assessed for cervical and endometrial infection using AC2 (Hologic, Marlborough, 105 MA) NAAT with overall infection rates of 67% and 8.5% for CT and NG, respectively. M. genitalium 106 (MG) infection was determined using the Aptima MG NAAT (Hologic).

107

108 16S library construction and characterization. Cervicovaginal swab samples available from 246 109 women enrolled in TRAC were processed for 16S rRNA gene microbiome profiling [11]. In brief, 100 cervicovaginal microbial communities present in participant specimens were profiled by 111 sequencing the V4 region of 16S rRNA gene using Illumina sequencing. The 16S rRNA amplicon 112 sequencing data was processed at the level of inferred amplicon sequence variants (ASVs) using 113 USEARCH v11 [15]. The raw sequencing data supporting the conclusions of this article is publicly

114 available at NCBI's Short Read Archive (SRA) under BioProject accession number115 PRJNA1136868.

116

PCR template purification from residual diagnostic samples. DNA was extracted as previously published using a Quick-DNA Universal Kit (Zymo Research, Irvine, California, USA) from 100 μL to 300 μL of reserved cervical swab eluates. Chlamydial and/or mycoplasmal loads were measured by quantitative PCR [1] targeting the 16SrRNA gene [16] or the highly conserved MG190 locus [10], respectively. Primers directed against the *parA* pseudogene [17], 16S rRNA and 23S rRNA loci [18] were similarly used to validate and/or quantify NG abundance.

123

124 PCR amplification and sequencing of 23S rRNA alleles. Amplification conditions for detection of 125 SNPs in C. trachomatis 23S were as described [19]. The melting temperature was raised to 98°C 126 for optimal activation of the high fidelity, proof-reading enzyme Phusion (ThermoFisher). Samples 127 were processed independently in a dedicated PCR hood to minimize risk of cross-contamination 128 during analysis. Two rounds of amplification were required to recover sufficient product which was 129 cleaned and concentrated using a DNA Clean and Concentrate kit (Zymo) before sequencing in 130 forward and reverse directions using V3 region primers [19]. Two patient samples that had tested 131 positively using the AC2 test were also analyzed as controls. Sequences generated via Sanger 132 sequencing were aligned against the published sequence using Clone Manager Professional 133 Version 11 (Sci Ed Software LLC, Westminster, CO). Residual cervical templates were used from 134 profiled participants except for 3-209, for whom only endometrium-extracted DNA remained 135 available for analysis.

Statistical analysis. The nonparametric Spearman rank correlation coefficient was calculated to assess the overall correlation between CT 16S rRNA gene DNA copy numbers measured by qPCR and the raw read counts of CT 16S rRNA gene from microbiome sequencing analysis using

R function 'cor' [20]. The LOESS (Locally Weighted Scatter-plot Smoother) curve was estimated
and plotted using a 'geom\_smooth' function of the R 'ggplot2' package with default settings [21].
Abundance of NG-specific ASVs present in libraries from individuals testing positively with AC2
and those who tested negative were compared using a Mann-Whitney test (two tailed).

143

144 **Results**:

145 Detection of chlamydia-derived amplicon sequence variant (ASV) in 16S libraries derived from 146 vaginal swabs obtained from CT negative TRAC participants. Total DNA was extracted from "future use" vaginal swabs from a total of 246 TRAC participants for inclusion in a 16S rRNA gene-147 148 based sequencing analysis of the contribution of the cervicovaginal microbiome to ascending 149 chlamydial infection. Three samples were excluded based on DNA low integrity values after 150 extraction. We also excluded twenty-three samples due to the equivocal results of chlamydial 151 infection at the cervix and/or endometrium from clinical diagnostic testing. The remaining 220 152 samples were processed using the ASV-level analysis, resulting in 1,990 ASVs detected in total 153 from samples sequenced to the average depth of ~151,000 reads. Taxonomy annotations of 154 ASVs were based on sequence comparison against the 16S rRNA gene reference database RDP 155 version 19 [22] using the SINTAX algorithm [23]. We assessed the concordance of STI detection 156 by examining raw read counts of sexually transmitted pathogen-specific 16S rRNA genes vs 157 infections previously assessed by NAAT diagnostic tests (CT, NG, MG) (Fig. 1a) and quantified 158 via gPCR (CT [1], Fig. 1b). About 58% (83 of 143) samples from participants whose tests were 159 positive for CT at enrollment had non-zero 16S rRNA gene read counts (Fig. 1a). Similarly, 85% 160 (17 of 20) samples from participants whose tests were postive for NG, and 15.8% (6 of 38) 161 samples from MG positive enrollees had non-zero 16S rRNA gene read counts. Overall, there 162 was modest correlation (Spearman = 0.575) between the two CT quantification methods (Fig. 163 1b).

164 Based on clinical diagnostic results obtained at enrollment, the TRAC participants were 165 classified into three groups: 1) Uninfected; 2) Endo- participants with CT infection detected only 166 in their cervix; 3) Endo+ participants who tested positively for CT in cervix and endometrium. 167 There were no TRAC enrollees whose tests were positive only in the endometrial sample. 168 Comparing ASV abundances between CT-positive (Endo- and Endo+) and CT-negative (control) 169 women, we were surprised to detect 16S ASV within libraries derived from samples from women 170 who had been assigned "uninfected" (N=7) based on the results of NAAT testing (Fig. 1a). These 171 results correlated with estimated chlamydial abundance derived from a previously performed 172 auantitative 16S PCR assay (Fig. 1b and Table 1), suggesting that attributing the original results 173 to external or cross-contamination was incorrect. A review of these participants' clinical data 174 revealed that they were mostly asymptomatic (5/7), one had reported experiencing dysuria, consistent with >10 leucocytes detected per high power field in her urine sample with irregular 175 176 vaginal bleeding and another reported dyspareunia and abnormal vaginal discharge. Clinical 177 findings upon pelvic examination were unremarkable for all. Three of the seven participants within 178 this group reported contact with a CT infected partner in the three months prior to their enrollment 179 but had yet to be treated.

180

Table 1. TRAC participants with discrepant clinical and molecular CT detection									
Sample	Clinical testing 16S rRNA read counts 16S qPCR*								
ID	(CT, MG, NG)	in ASV analysis							
			Сх	Endo					
3-101	CT-/MG-/NG-	1	78	919					
3-144		16	420	87					
3-145		146	128800	35					
3-148		111	3839	457					
3-201		55	1495	721					
3-226		31	1640	105					
3-209	CT-/MG+/NG-	4	13000	62680					

\*Chlamydial 16S rDNA copies/swab [1].

181

182 In the context of the TRAC cohort, reasons for false negative CT NAAT test results, other 183 than testing failures detected at or during performance e.g., compromised reagents or automated 184 run failure (batch specific), include inadequate sampling at the anatomical site or an unanticipated 185 flaw in the diagnostic test. All NAAT tests were run within temporal parameters appropriate for 186 clinical STI testing, so batch-specific effects did not serve as an explanation for these 187 discrepancies because the participants were not recruited contemporaneously. Testing of an 188 endometrial biopsy might result in a false negative because the entire endometrial lining is not 189 sampled, the amounts of tissue obtained may vary [7], and the region of specimen dedicated to 190 NAAT testing is small [10]. However, cervical testing, particularly when performed by highly 191 trained practitioners, is robust [24, 25]. Several publications from Northern Europe have reported 192 instances of false negative testing specifically associated with the AC2 test [12, 13, 26, 27] arising 193 from probe-avoidant mutations at the chlamydial 23S rRNA locus [19]. Speculating that this might 194 explain our discrepant results, we attempted to amplify the relevant V3 region from cervically or 195 endometrially derived templates that had been extracted from residual diagnostic swab eluates. 196 In all instances we were successful using the protocol and primers used by Hokynar et al. [19], 197 further confirming the presence of chlamydial DNA in the clinical samples. We detected a G-A 198 substitution at 1523 in the samples of all seven test-discrepant participants (Fig. 2) when these 199 products were sequenced. NAAT positively-testing samples (N=2) from the cohort were wild type 200 at this position (data not shown). These data indicated that at least one probe-avoidant variant of 201 CT was circulating in the region between May 2012 and February 2014, the time window between 202 enrollments of our earliest and latest discrepant TRAC participants.

16S rRNA gene microbiome analysis also revealed a total of five participants with
 discrepant NG AC2 testing enrolled from April 2011 to July 2013 (Fig. 1A, Table 2), including one
 participant, 3-209, who also tested discrepantly for CT (Table 1). One participant reported mild

206 urinary symptoms with abnormal vaginal discharge and irregular bleeding and one other 207 participant reported bleeding with intercourse. Clinical findings on pelvic examination were 208 noteworthy for bleeding with cervical contact for four of five participants but were otherwise 209 unremarkable. Only one of these participants reported contact with an infected partner within the 210 preceding three months but had not received treatment.

211 The genus Neisseria includes a group of commensal species, N. subflava, N. mucosa, N. 212 elongata, in addition to the important human pathogens, N. gonorrhoeae and N. meningitidis with 213 the potential for genetic exchange between these naturally competent microorganisms [28] so we 214 initially speculated that the ASV detected lacked discriminatory capacity. However, alignment of 215 the 16S V4 sequence from N. gonorrhoeae with the 35 Neisseria species included in the RDP 216 v18 database, revealed that ASV ZOtu95, detected in the discrepant samples, was highly specific, 217 aligning with 100% identity between bases 535-787 of the 1544 nucleotide V4 region. This 218 suggested that the 16S ASV detected in libraries generated from the vaginal swabs reflected true 219 gonococcal infection. Next, we compared the number of ZOtu95 reads from discordant individuals 220 with those detected in libraries generated from TRAC participants with concordant NG detection 221 (Table 2) as a surrogate for pathogen load. The number of reads counted in NG+ samples ranged 222 across four orders of magnitude but participant swab samples yielding libraries with ≤6 counts still 223 tested positively via AC2 and no difference was detected between the groups using the non-224 parametric Mann-Whitney test (P=0.4116). Low levels of infection may have contributed to 225 differential sampling of bacterial populations present at the cervix (diagnostic) and in the vagina 226 (16S analysis). Quantifying NG by qPCR in residual template was difficult because of the minimal 227 amount of cervical DNA remaining and the potential for high genetic variability between strains. 228 Using primers that targeted multicopy (16S, 23S rRNA) and single copy (ParA pseudogene) loci, 229 with genomic DNA extracted from N. gonorrhoeae strain FA19 as a positive control [29], we 230 performed qPCR on diagnostic swab eluates or the 16S template that remained from discrepant

231 NG+ participants (Table 2). Evaluating the performance of the primer pairs using material 232 obtained from participants testing positively for NG infection, we observed that only 8 of the 17 233 samples consistently yielded PCR product for all 3 loci, while 6, were positive for 1-2. We were 234 unsuccessful in amplifying material from the remaining 3 samples. Overall, successful 235 amplification of the targets did not reflect abundance of 16S read counts in participants' 16S rRNA 236 libraries. For samples derived from participants who had tested negatively clinically but with 237 ZOtu95 reads detected via 16S rRNA microbiome profiling, all tested positively for at least one 238 multicopy locus.

239 With no source for cross-contamination available in the lab performing the 16S rRNA 240 analysis, we also looked retrospectively at participant enrollment dates to exclude the remote 241 possibility of cross- or environmental contamination [30] occurring during sample collection or 242 NAAT testing. In only one instance did we observe enrollment of a discrepant NG- (3-121) and a 243 confirmed clinically NG+ participant within the same 48-hour window (3-120). However, the 244 presence of additional, neisserial species ASVs in the library generated from 3-120 only (Table 245 2), is inconsistent with contamination of the discrepant NG- sample by material derived from this 246 diagnostic swab.

247

#### 248 Discussion:

This study revealed that non-congruent CT infection outcomes that we detected between clinical diagnostics and 16S analysis for cervicovaginal samples collected from TRAC enrollees are best explained as resulting from false negative NAAT tests. The point mutation in 23S that we detected in discordant TRAC participants has been associated with reduced probe binding with the original AC2 assay. The G1523A variant was detected in the UK after clinical samples were screened for probe-avoiding mutants that might be in circulation [12] and in Denmark [13]. This is

255 the first report of its detection in the United States although Katz et al., reported other 23S variants 256 that mapped to A1518G or G1526A escaping detection in specimens collected in a five-week 257 window, spanning late 2019 to early 2020 (2 of 401) [31]. Our retrospective analysis suggests 258 that diagnostic-avoidant CT was already circulating in western Pennsylvania. USA by 2012 or 259 possibly earlier. The first participants of the TRAC cohort enrolled in February 2011, but we did 260 not identify diagnostically discordant enrollment samples collected prior to May 2012. Provided 261 that this mutation does not impair chlamydial fitness, it is likely that it continues to circulate. The 262 first 23S SNP variant escaping detection by the AC2 assay, FI-nvCT (C1515T), is still present in 263 Finland at an estimated prevalence of 1.8% [32]. Fortunately, the deficit in the clinical test has 264 been recognized and remediated by the manufacturer via incorporation of an additional 265 chlamydial target [26] to improve reliability.

266 While discordancy between the clinical diagnostic assay for CT 23S RNA and detection 267 of CT 16S rRNA, whether by gPCR or in the 16S rRNA libraries generated for microbiome analysis 268 was ultimately elucidated by our identification of a genetic variant, the basis for the discrepancy 269 of detection of NG 16S ASVs in participant samples from study participants who were diagnosed 270 NG negative via the AC2 assay is not easily explained. The NG probe of the AC2 assay is directed 271 against 16S rRNA and is both sensitive and highly specific [33-35]. Multiplex diagnostic tests have 272 been reported to have high sensitivity and high concordance with standard nucleic acid 273 amplification testing [36, 37] with a 4-in-1 test for CT, NG, Trichomonas vaginalis, and M. 274 genitalium receiving recent clearance by the FDA [38]. False positive results for NG have been 275 obtained arising from recombination between 16S loci of N. meningitidis, now recognized as a 276 urogenital pathogen [39-42] and NG [43, 44]. The presence of multiple ribosomal RNA operons 277 in this genus [45] elevates the risk for even rare recombination events to become fixed in the 278 population. Should the inverse recombination event also occur, and NG acquire 16S copies from 279 other neisserial species, this could lead to reduced sensitivity of currently available diagnostic 280 tests, the consequences of which could negatively impact infection control and promote spread of diagnostic-avoidant mutants as was observed with Swedish nvCT [46, 47]. Identification of highly conserved, alternative targets for detection of NG has proven extremely challenging, so it is not surprising that we were unable to positively confirm the presence of genomic DNA in all the samples. However, we were also unable to amplify even multicopy targets from specimens collected from participants that tested positively by clinical NAAT, raising the possibility of low abundance bacteria that are asymmetrically distributed between the cervix and vaginal vault of discrepant enrollees.

288 Fortunately, study participants of TRAC were not harmed by failure to detect their CT 289 and/or NG infection because all recipients were administered appropriate antibiotic therapy at 290 enrollment regardless of their NAAT result. Appropriately, health care providers are moving from 291 empiric syndromic treatment of patients at risk for STIs to pathogen-specific treatment guided by 292 results of molecular tests [48]. Untreated CT and NG infections can lead to severe complications 293 including PID, infertility, ectopic pregnancy and chronic pelvic pain in women. While NAATs are 294 highly accurate, our study demonstrates that clinicians and epidemiologists should remain vigilant 295 for potential CT or NG variants evading current approved NAATs such as detection of negative 296 test results in a recently exposed individual, or a decline in overall rates of infection in a particular 297 geographic location as occurred with Swedish nvCT [46, 47].

298

# 299 **Declarations**:

300 **Ethics approval and consent to participate:** The study protocol was approved by the 301 institutional review boards for human research of the University of Pittsburgh (#PRO10010159) 302 and the University of North Carolina (#13-3074). All participants provided written informed consent 303 at the time of enrollment.

304 **Consent for publication:** Not applicable.

Availability of data and materials: The raw sequencing data supporting the conclusions of this article is publicly available at NCBI's Short Read Archive (SRA) under BioProject accession number PRJNA1136868.

- 308 **Competing interests:** The authors declare that they have no competing interests.
- 309 **Funding:** This work was supported by the National Institute of Allergy and Infectious Diseases
- 310 via U19 Al084024 and R01 Al170959.
- 311 Authors' contributions: SJ, KSY, XP, and CMO designed research studies. HCW and SLH
- 312 directed collection of participant samples and performance of diagnostic testing. TT, HC, TY and

313 PB performed experiments. SJ, TT, HB, HC, and XP analyzed data. SJ, KSY, TD, XP, and CMO

314 wrote the manuscript. All authors reviewed the manuscript.

315 Acknowledgements: We thank the women who agreed to participate in this study; Ingrid Macio,

316 Melinda Petrina, Carol Priest, Abi Jett, and Lorna Rabe for their efforts in the clinic and the

- 317 microbiology laboratory; and the staff at the Allegheny County Health Department STD Clinic, for
- their efforts. We would also like to acknowledge the contribution of Dr. Ian Huntress, who sadly
- 319 passed away during the performance of these studies.
- 320

# 321 References:

322	1.	Russell AN, Zheng X, O'Connell CM, Taylor BD, Wiesenfeld HC, Hillier SL, Zhong W,
323		Darville T: Analysis of Factors Driving Incident and Ascending Infection and the
324		Role of Serum Antibody in Chlamydia trachomatis Genital Tract Infection. J Infect
325		<i>Dis</i> 2016, <b>213</b> (4):523-531.
326	2.	Russell AN, Zheng X, O'Connell CM, Wiesenfeld HC, Hillier SL, Taylor BD, Picard MD,
327		Flechtner JB, Zhong W, Frazer LC et al: Identification of Chlamydia trachomatis
328		Antigens Recognized by T Cells From Highly Exposed Women Who Limit or
329		Resist Genital Tract Infection. J Infect Dis 2016, 214(12):1884-1892.
330	3.	Liu C, Mokashi Neha V, Darville T, Sun X, O'Connell Catherine M, Hufnagel K,
331		Waterboer T, Zheng X: A Machine Learning-Based Analytic Pipeline Applied to
332		Clinical and Serum IgG Immunoproteome Data To Predict Chlamydia trachomatis
333		Genital Tract Ascension and Incident Infection in Women. Microbiology Spectrum
334		2023, <b>0</b> (0):e04689-04622.
335	4.	Liu C, Hufnagel K, O'Connell CM, Goonetilleke N, Mokashi N, Waterboer T, Tollison TS,
336		Peng X, Wiesenfeld HC, Hillier SL et al: Reduced Endometrial Ascension and
337		Enhanced Reinfection Associated With Immunoglobulin G Antibodies to Specific
338		Chlamydia trachomatis Proteins in Women at Risk for Chlamydia. J Infect Dis 2022,
339		<b>225</b> (5):846-855.
340	5.	Darville T, Albritton HL, Zhong W, Dong L, O'Connell CM, Poston TB, Quayle AJ,
341		Goonetilleke N, Wiesenfeld HC, Hillier SL et al: Anti-chlamydia IgG and IgA are
342		insufficient to prevent endometrial chlamydia infection in women, and increased
343		anti-chlamydia IgG is associated with enhanced risk for incident infection. Am $J$
344		Reprod Immunol 2019, <b>81</b> (5):e13103.

345	6.	Poston TB, Lee DE, Darville T, Zhong W, Dong L, O'Connell CM, Wiesenfeld HC, Hillier
346		SL, Sempowski GD, Zheng X: Cervical Cytokines Associated With Chlamydia
347		trachomatis Susceptibility and Protection. J Infect Dis 2019, 220(2):330-339.
348	7.	Zheng X, O'Connell CM, Zhong W, Nagarajan UM, Tripathy M, Lee D, Russell AN,
349		Wiesenfeld H, Hillier S, Darville T: Discovery of Blood Transcriptional Endotypes in
350		Women with Pelvic Inflammatory Disease. J Immunol 2018, 200(8):2941-2956.
351	8.	Zheng X, Zhong W, O'Connell CM, Liu Y, Haggerty CL, Geisler WM, Anyalechi GE,
352		Kirkcaldy RD, Wiesenfeld HC, Hillier SL et al: Host Genetic Risk Factors for
353		Chlamydia trachomatis-Related Infertility in Women. J Infect Dis 2021,
354		<b>224</b> (Supplement_2):S64-s71.
355	9.	Zheng X, O'Connell CM, Zhong W, Poston TB, Wiesenfeld HC, Hillier SL, Trent M,
356		Gaydos C, Tseng G, Taylor BD et al: Gene Expression Signatures Can Aid
357		Diagnosis of Sexually Transmitted Infection-Induced Endometritis in Women.
358		Front Cell Infect Microbiol 2018, 8(307):307.
359	10.	Taylor BD, Zheng X, O'Connell CM, Wiesenfeld HC, Hillier SL, Darville T: Risk factors
360		for Mycoplasma genitalium endometritis and incident infection: a secondary data
361		analysis of the T cell Response Against Chlamydia (TRAC) Study. Sex Transm
362		Infect 2018, <b>94</b> (6):414-420.
363	11.	Jeong S, Tollison T, Brochu H, Chou H, Huntress I, Yount KS, Zheng X, Darville T,
364		O'Connell CM, Peng X: Cervicovaginal microbial features predicts
365		<em>Chlamydia trachomatis</em> spread to the upper genital tract of
366		infected women. <i>bioRxiv</i> 2024:2024.2011.2026.625070.
367	12.	Cole MJ, Davis GS, Fifer H, Saunders JM, Unemo M, Hadad R, Roberts DJ, Fazal M,
368		Day MJ, Minshull J et al: No widespread dissemination of Chlamydia trachomatis
369		diagnostic-escape variants and the impact of Neisseria gonorrhoeae positivity on
370		the Aptima Combo 2 assay. Sex Transm Infect 2022, 98(5):366-370.

371	13.	Hadad R, Jensen JS, Westh H, Gronbaek I, Schwartz LJ, Nielsen L, Vang TM, Nielsen
372		R, Weinreich LS, Skov MN et al: A Chlamydia trachomatis 23S rRNA G1523A variant
373		escaping detection in the Aptima Combo 2 assay (Hologic) was widespread
374		across Denmark in July-September 2019. APMIS 2020, 128(6):440-444.
375	14.	Roberts DJ, Davis GS, Cole MJ, Naik D, Maru H, Woodford N, Muir P, Horner P, Simms
376		I, Thickett G et al: Prevalence of new variants of Chlamydia trachomatis escaping
377		detection by the Aptima Combo 2 assay, England, June to August 2019. Euro
378		<i>Surveill</i> 2019, <b>24</b> (38).
379	15.	Edgar RC: Search and clustering orders of magnitude faster than BLAST.
380		Bioinformatics 2010, <b>26</b> (19):2460-2461.
381	16.	O'Connell CM, Brochu H, Girardi J, Harrell E, Jones A, Darville T, Sena AC, Peng X:
382		Simultaneous profiling of sexually transmitted bacterial pathogens, microbiome,
383		and concordant host response in cervical samples using whole transcriptome
384		sequencing analysis. Microb Cell 2019, 6(3):177-183.
385	17.	Hazel A, Ponnaluri-Wears S, Davis GS, Low BS, Foxman B: High prevalence of
386		Neisseria gonorrhoeae in a remote, undertreated population of Namibian
387		pastoralists. Epidemiol Infect 2014, 142(11):2422-2432.
388	18.	Mitchev N, Singh R, Ramsuran V, Ismail A, Allam M, Kwenda S, Mnyameni F, Garrett N,
389		Swe Swe-Han K, Niehaus AJ et al: Assessment of Antibiotic Resistance and Efflux
390		Pump Gene Expression in Neisseria Gonorrhoeae Isolates from South Africa by
391		Quantitative Real-Time PCR and Regression Analysis. Int J Microbiol 2022,
392		<b>2022</b> :7318325.
393	19.	Hokynar K, Rantakokko-Jalava K, Hakanen A, Havana M, Mannonen L, Jokela P,
394		Kurkela S, Lappalainen M, Unemo M, Puolakkainen M: The Finnish new variant of
395		Chlamydia trachomatis with a single nucleotide polymorphism in the 23S rRNA

396		target escapes detection by the Aptima Combo 2 test. Microorganisms 2019,
397		<b>7</b> (8):227.
398	20.	R: A Language and Environment for Statistical Computing. In. Edited by Team RC:
399		R Foundation for Statistical Computing; 2015.
400	21.	Wickham H: ggplot: Elegant graphics for data analysis. New York: Springer-Verlag
401		2016.
402	22.	Cole JR, Wang Q, Fish JA, Chai B, McGarrell DM, Sun Y, Brown CT, Porras-Alfaro A,
403		Kuske CR, Tiedje JM: Ribosomal Database Project: data and tools for high
404		throughput rRNA analysis. Nucleic Acids Res 2014, 42(Database issue):D633-642.
405	23.	Robert CE: SINTAX: a simple non-Bayesian taxonomy classifier for 16S and ITS
406		sequences. <i>bioRxiv</i> 2016:074161.
407	24.	Cook RL, Hutchison SL, Ostergaard L, Braithwaite RS, Ness RB: Systematic review:
408		noninvasive testing for Chlamydia trachomatis and Neisseria gonorrhoeae. Ann
409		Intern Med 2005, <b>142</b> (11):914-925.
410	25.	Centers for Disease C, Prevention: Recommendations for the laboratory-based
411		detection of Chlamydia trachomatis and Neisseria gonorrhoeae2014. MMWR
412		Recomm Rep 2014, <b>63</b> (RR-02):1-19.
413	26.	Unemo M, Hansen M, Hadad R, Puolakkainen M, Westh H, Rantakokko-Jalava K,
414		Thilesen C, Cole MJ, Boiko I, Lan PT et al: Sensitivity, specificity, inclusivity and
415		exclusivity of the updated Aptima Combo 2 assay, which provides detection
416		coverage of the new diagnostic-escape Chlamydia trachomatis variants. BMC
417		Infect Dis 2020, <b>20</b> (1):419.
418	27.	Rantakokko-Jalava K, Hokynar K, Hieta N, Keskitalo A, Jokela P, Muotiala A, Jokiranta
419		TS, Kuusela R, Sarkkinen H, Aittoniemi J et al: Chlamydia trachomatis samples
420		testing falsely negative in the Aptima Combo 2 test in Finland, 2019. Euro Surveill
421		2019, <b>24</b> (22).

4	22	28.	Smith NH, Holmes EC, Donovan GM, Carpenter GA, Spratt BG: Networks and groups
4	23		within the genus Neisseria: analysis of argF, recA, rho, and 16S rRNA sequences
4	24		from human Neisseria species. Mol Biol Evol 1999, 16(6):773-783.
4	25	29.	Abrams AJ, Trees DL, Nicholas RA: Complete Genome Sequences of Three
4	26		Neisseria gonorrhoeae Laboratory Reference Strains, Determined Using PacBio
4	27		Single-Molecule Real-Time Technology. Genome Announc 2015, 3(5).
4	28	30.	Ramsden S, Ovens K, Griffiths J, Muir P, Steele-Nicholson A, Horner PJ:
4	29		Environmental contamination by Chlamydia trachomatis and Neisseria
4	30		gonorrhoeae: is it time to change our infection control practices? Results of a
4	31		regional study. Sex Transm Infect 2023, 99(1):35-40.
4	32	31.	Katz SS, Danavall DC, Morris MR, Herrod BP, Dale SE, Nye MB, Kersh EN, Kirkcaldy
4	33		RD, Raphael BH: Chlamydia trachomatis Variants Escaping Detection in the
4	34		Aptima Combo 2 Assay in the United States. Sex Transm Dis 2022, 49(6):448-452.
4	35	32.	Puolakkainen M, Mannonen L, Unemo M: The diagnostic-escape Finnish new variant
4	36		of Chlamydia trachomatis first described in 2019 remains present in Finland three
4	37		years after the introduction of an updated Aptima Combo 2 assay. Clin Microbiol
4	38		Infect 2023, <b>29</b> (5):658-659.
4	39	33.	Bristow CC, McGrath MR, Cohen AC, Anderson LJ, Gordon KK, Klausner JD:
4	40		Comparative evaluation of two nucleic acid amplification tests for the detection of
4	41		Chlamydia trachomatis and Neisseria gonorrhoeae at extragenital sites. Sexually
4	42		transmitted diseases 2017, <b>44</b> (7):398.
4	43	34.	Golparian D, Tabrizi SN, Unemo M: Analytical specificity and sensitivity of the
4	44		APTIMA Combo 2 and APTIMA GC assays for detection of commensal Neisseria
4	45		species and Neisseria gonorrhoeae on the Gen-Probe Panther instrument.
4	46		Sexually Transmitted Diseases 2013, <b>40</b> (2):175-178.

447	35.	Tabrizi SN, Unemo M, Limnios AE, Hogan TR, Hjelmevoll S-O, Garland SM, Tapsall J:
448		Evaluation of six commercial nucleic acid amplification tests for detection of
449		Neisseria gonorrhoeae and other Neisseria species. Journal of clinical microbiology
450		2011, <b>49</b> (10):3610-3615.
451	36.	Matysiak C, Cheng A, Kirby JE: Evaluation of the Abbott Alinity m STI assay for
452		diagnosis of the primary causes of sexually transmitted infections in the United
453		States. Pract Lab Med 2023, 36:e00332.
454	37.	Kriesel JD, Bhatia AS, Barrus C, Vaughn M, Gardner J, Crisp RJ: Multiplex PCR
455		testing for nine different sexually transmitted infections. Int J STD AIDS 2016,
456		<b>27</b> (14):1275-1282.
457	38.	Administration USFD: Alinity m CMV Assay - P210022. In.; 2022.
458	39.	Urra E, Alkorta M, Sota M, Alcalá B, Martínez I, Barrón J, Cisterna R: Orogenital
459		transmission of Neisseria meningitidis serogroup C confirmed by genotyping
460		techniques. Eur J Clin Microbiol Infect Dis 2005, 24(1):51-53.
461	40.	Katz AR, Chasnoff R, Komeya A, Lee MV: Neisseria meningitidis urethritis: a case
462		report highlighting clinical similarities to and epidemiological differences from
463		gonococcal urethritis. Sex Transm Dis 2011, 38(5):439-441.
464	41.	Kanemitsu N, Hayashi I, Satoh N, Hayakawa T, Mitsuya H, Hayase Y, Hiramoto K,
465		Kojima M: Acute urethritis caused by Neisseria meningitidis. Int J Urol 2003,
466		<b>10</b> (6):346-347.
467	42.	Bazan JA, Peterson AS, Kirkcaldy RD, Briere EC, Maierhofer C, Turner AN, Licon DB,
468		Parker N, Dennison A, Ervin M et al: Notes from the Field: Increase in Neisseria
469		meningitidis-Associated Urethritis Among Men at Two Sentinel Clinics -
470		Columbus, Ohio, and Oakland County, Michigan, 2015. MMWR Morb Mortal Wkly
471		Rep 2016, <b>65</b> (21):550-552.

472	43.	Walcher M, Skvoretz R, Montgomery-Fullerton M, Jonas V, Brentano S: Description of
473		an unusual Neisseria meningitidis isolate containing and expressing Neisseria
474		gonorrhoeae-Specific 16S rRNA gene sequences. J Clin Microbiol 2013,
475		<b>51</b> (10):3199-3206.
476	44.	Sukhum KV, Jean S, Wallace M, Anderson N, Burnham CA, Dantas G: Genomic
477		Characterization of Emerging Bacterial Uropathogen Neisseria meningitidis,
478		Which Was Misidentified as Neisseria gonorrhoeae by Nucleic Acid Amplification
479		Testing. J Clin Microbiol 2021, 59(2).
480	45.	Klappenbach JA, Saxman PR, Cole JR, Schmidt TM: rrndb: the Ribosomal RNA
481		Operon Copy Number Database. Nucleic Acids Res 2001, 29(1):181-184.
482	46.	Ripa T, Nilsson P: A variant of Chlamydia trachomatis with deletion in cryptic
483		plasmid: implications for use of PCR diagnostic tests. EuroSurveill 2006,
484		<b>11</b> (11):E061109.
485	47.	Unemo M, Seth-Smith HM, Cutcliffe LT, Skilton RJ, Barlow D, Goulding D, Persson K,
486		Harris SR, Kelly A, Bjartling C et al: The Swedish new variant of Chlamydia
487		trachomatis: genome sequence, morphology, cell tropism and phenotypic
488		characterization. Microbiology, 156(Pt 5):1394-1404.
489	48.	Karellis A, Naeem F, Nair S, Mallya SD, Routy JP, Gahagan J, Yansouni CP, Kim J, Pai
490		NP: Multiplexed rapid technologies for sexually transmitted infections: a
491		systematic review. Lancet Microbe 2022, 3(4):e303-e315.
492		

Sample ID	Diagr tes	nostic st		qPCR†					
	Cervix	Endo	ZOtu95: N_gonorrhoeae	ZOtu141: N_subflava	ZOtu264: N_mucosa	ZOtu1566: N_elongata	16S	23S	ParA
3-121	-121		130	130 0		0	+	+	-
3-140	-	-	123	0	0	0	+	+	+
3-146	-	-	106	0	0	0	+	+	ND
3-151	-	-	6	0	0	0	+	-	+
3-209			1	1 0 0 0		0	-	+	ND
3-012	+	-	471	0	0	0	+	+	+
3-026	+	-	10	0	0	0	-	-	-
3-052	+	-	10	0	0	0	-	+	-
3-089	+	-	24	0	0	0	-	+	+
3-091	+	-	6	0	0	0	+	+	+
3-112	+	-	1032	0	0	0	+	+	+
3-114	+	-	85	0	0	0	-	-	-
3-120	+	-	19	211	131	0	-	+	-
3-122	+	-	110	0	0	0	+	+	+
3-124	+	-	927	0	0	0	-	+	-
3-133	+	-	3	0	0	0	-	-	-
3-136	+	-	2	0	1	0	+	+	-
3-177	+	-	180	0	0	0	+	+	+
3-208	+	-	1151	0	0	0	-	+	-
3-212	+	-	9	0	0	0	+	+	+
3-223	+	-	206	0	0	0	+	+	+
3-235	+	-	349	0	0	0	+	+	+

**Table 2.** *Neisseria sp.* transcripts detected by 16S ASV analysis and genes detected by qPCR in diagnostic-discrepant or NG+ TRAC participants.

†Assay performed with diagnostic swab eluate or vaginal swab template used for 16S rRNA microbiome analysis. ND not done because specimen was insufficient or unavailable.

494

495

496

497





500

**Figure 1. STI-derived 16S transcripts detected in vaginal swabs**. a) 16S rRNA gene read counts of STIs stratified by infection status at enrollment. b) Concordance between CT 16S rRNA gene read counts versus CT burden by qPCR, where samples are colored by infection status at enrollment. A LOESS curve is shown in red and Spearman correlation in the bottom-right. CT, *Chlamydia trachomatis*; GC, *N. gonorrhoeae*; MG, *M. genitalium* 

507

		1450 I	1460 I	1470 I	1480 I	1490 I	1500 I	1510 I	1520	1530 I	1540 I	1550 I	1560	1570 I	1580 I
Reference	1446	gtccgtagag	gcgatgagaa	cggttagtag	gcaaatccgc	taacataaga	atcaggtcgcg	gatcaagggga	atcttcggg	ggaaccgatgg	tgtggagcga	aggctttcaag	gaaataattt	tagctgttga	atggtgaccgt
3_144	21	gtccgtagag	gcgatgagaa	cggttagtag	gcaaatccgc	taacataaga	atcaggtcgcg	gatcaagggga	atcttcgga	ggaaccgatgg	tgtggagcga	aggctttcaag	aaataattt	tagctgttga	atggtgaccgt
3_145	22	gtccgtagag	gcgatgagaa	cggttagtag	gcaaatccgc	taacataaga	atcaggtcgcg	gatcaagggga	atcttcgga	ggaaccgatgg	tgtggagcga	aggctttcaag	gaaataattt	ctagctgttga	atggtgaccgt
3_148	23	gtccgtagag	gcgatgagaa	cggttagtag	gcaaatccgc	taacataaga	atcaggtcgcg	gatcaagggga	atcttcgga	ggaaccgatgg	tgtggagcga	aggctttcaag	gaaataattt	ctagctgttga	atggtgaccgt
3-226	22	gtccgtagag	gcgatgagaa	cggttagtag	gcaaatccgc	taacataaga	atcaggtcgcg	gatcaagggga	atcttcgga	ggaaccgatgg	tgtggagcga	aggctttcaag	gaaataattt	ctagctgttga	atggtgaccgt
3_209	22	gtccgtagag	gcgatgagaa	cggttagtag	gcaaatccgc	taacataaga	atcaggtcgcg	gatcaagggga	atcttcgga	ggaaccgatgg	tgtggagcga	aggctttcaag	gaaataattt	ctagctgttga	atggtgaccgt
3_101	22	gtccgtagag	gcgatgagaa	cggttagtag	gcaaatccgc	taacataaga	atcaggtcgcg	gatcaagggga	atcttcgga	ggaaccgatgg	tgtggagcga	aggctttcaag	gaaataattt	ctagctgttga	atggtgaccgt
3_201	22	gtccgtagag	gcgatgagaa	cggttagtag	gcaaatccgc	taacataaga	atcaggtcgcg	gatcaagggga	atcttcgga	ggaaccgatgg	tgtggagcga	aggctttcaag	gaaataattt	tagctgttg	atggtgaccgt

508

- 509 Figure 2. Portion of sequence alignment of V3 amplified PCR products from discrepant
- 510 TRAC participant specimens revealing a g to a substitution at 1523 in the 23S rDNA locus.
- 511 PCR products from two representative CT+ samples, as determined by AC2 diagnostic test were
- 512 wild type at this position (data not shown).

513